Utama › Purpura Trombositopenik Idiopatik › North Carolina
Kajian klinikal Purpura Trombositopenik Idiopatik di North Carolina
7 kajian untuk Purpura Trombositopenik Idiopatik sedang mencari peserta di lokasi di North Carolina.
Bandar di North Carolina
Teks kajian rasmi (Bahasa Inggeris)
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Duke University Hospital, Durham
- East Carolina University, Greenville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06722235Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
- East Carolina University, Greenville
Mengambil pesertaFasa 2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 14 Sep 2026 · NCT07095127A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
- East Carolina University, Greenville
Mengambil pesertaFasa 3
Umur 18 hingga 70 · Semua jantina · Dikemas kini 11 Sep 2026 · NCT07059000A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Duke University Hospital, Durham
- East Carolina University, Greenville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06948318Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- Universtity of North Carolina at Chapel Hill, Chapel Hill
Mengambil pesertaFasa 1
Umur 18 hingga 85 · Semua jantina · Dikemas kini 22 Jul 2026 · NCT06371417Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- East Carolina University, Greenville
Mengambil pesertaFasa 2
Umur 18 hingga 70 · Semua jantina · Dikemas kini 12 Mei 2026 · NCT05070845A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
- Duke University Medical Center, Durham
- Brody School of Medicine at East Carolina University, Greenville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Mei 2026 · NCT06544499Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.